Coronary stents: Looking forward

Journal of the American College of Cardiology

Volumn 56, Issue 10 SUPPL., 2010, Pages

  Garg, Scot ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

biodegradable polymer stents; biodegradable stents; coronary stents; drug eluting stents; polymer free drug eluting stents

Indexed keywords

BIOLIMUS; CARBONIC ACID; CHROMIUM; COBALT; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYOLIMUS; NOVOLIMUS; PACLITAXEL; PLATINUM; POLY(IOIODINATED DESAMINOTYROSYL TYROSINE ETHYL ESTER)CARBONIC ACID; POLYCARBONATE; POLYLACTIC ACID; POLYLACTIDE; POLYMER; RAPAMYCIN; SALICYLIC ACID; UNCLASSIFIED DRUG; ZOTAROLIMUS;

BARE METAL STENT; BIFURCATION STENT; BIODEGRADABLE IMPLANT; CAROTID ARTERY BIFURCATION; CORONARY STENT; DRUG ELUTING STENT; FOLLOW UP; HUMAN; PRIORITY JOURNAL; REVIEW;

ABSORBABLE IMPLANTS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CLINICAL TRIALS AS TOPIC; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; HUMANS;

EID: 77956167248     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.06.008     Document Type: Review

References (197)

1. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 2007 1440 1455
2. B. Lagerqvist, S.K. James, and U. Stenestrand Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019
3. A.J. Nordmann, M. Briel, and H.C. Bucher Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis Eur Heart J 27 2006 2784 2814
4. S. Garg, and P.W. Serruys Benefits of and safety concerns associated with drug-eluting coronary stents Expert Rev Cardiovasc Ther 8 2010 449 470
5. S. Garg, P.W. Serruys, and Y. Onuma Three year clinical follow up of the XIENCE V Everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions The SPIRIT II Trial J Am Coll Cardiol Intv 2 2009 1190 1198
6. G.W. Stone, M. Midei, and W. Newman Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: 2-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial Circulation 119 2009 680 686
7. C. Hamm 5 years later and more than 20,000 patients studied: the ENDEAVOR clinical program Paper presented at: EuroPCR; May 19-22, 2009; Barcelona, Spain http://www.pcronline.com/Lectures/2009/5-years-later-and-more-than-20-000- patients-studied-the-ENDEAVOR-clinical-programme Accessed June 20, 2009
8. G.J. Wilson, G. Nakazawa, and R.S. Schwartz Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries Circulation 120 2009 141 149 12
9. A.V. Finn, F.D. Kolodgie, and J. Harnek Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents Circulation 112 2005 270 278
10. A.V. Finn, G. Nakazawa, and M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510
11. M. Joner, G. Nakazawa, and A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342
12. K.O. Niemela Biodegradable coating for drug-eluting stentsmore than a facelift? Eur Heart J 29 2008 1930 1931
13. I.T. Meredith, S. Worthley, and R. Whitbourn Clinical and angiographic results with the next-generation Resolute stent system a prospective, multicenter, first-in-human trial J Am Coll Cardiol Intv 2 2009 977 985
14. J.R. Costa Jr., A. Abizaid, and F. Feres EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions EuroIntervention 4 2008 53 58
15. A. Abizaid, J.R. Costa Jr., and F. Feres TCT-429: single center, first-in-man study of the elixir novolimus eluting coronary stent system with durable polymer 24-month clinical safety and efficacy results (abstr) Am J Cardiol 104 2009 158D
16. D.J. Kereiakes, L.A. Cannon, and R.L. Feldman Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial J Am Coll Cardiol 56 2010 264 271
17. Kereiakes D, Cannon LA, Feldman R, et al. TAXUS PERSEUS: a novel platinum chromium, thin-strut TAXUS Element stent for the treatment of de novo coronary stenoses. Paper presentet at: i2summit, American College of Cardiology; March 15, 2010; Atlanta, GA.
18. I.T. Meredith, S. Worthley, and R. Whitbourn The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial EuroIntervention 3 2007 50 53
19. K. Udipi, R.J. Melder, and M. Chen The next generation Endeavor Resolute stent: role of the BioLinx polymer system EuroIntervention 3 2007 137 139
20. I. Meredith, S. Worthley, and R. Whitbourn Long-term clinical outcomes with the next generation Resolute Stent System: a report of the 2-year follow-up from RESOLUTE clinical trial EuroIntervention 5 2010 692 697
21. TCT-414: Three-year follow-up of a new zotarolimus-eluting stent: results of the RESOLUTE first-in-man trial (abstr) Am J Cardiol 104 2009 153D 154D
22. P.W. Serruys, S. Silber, and S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 123 135
23. P.W. Serruys, S. Garg, and A. Abizaid A randomised comparison of novolimus-eluting and zotarolimus-eluting stents: 9-month results of the EXCELLA II study EuroIntervention 6 2010 195 205
24. A. Kastrati, J. Mehilli, and J. Dirschinger Intracoronary Stenting and Angiographic Results : Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial Circulation 103 2001 2816 2821
25. J. Pache, A. Kastrati, and J. Mehilli Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial J Am Coll Cardiol 41 2003 1283 1288
26. S. Dani, N. Kukreja, and P. Parikh Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study EuroIntervention 4 2008 59 63
27. Y. Han, Q. Jing, and B. Xu Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes J Am Coll Cardiol Intv 2 2009 303 309
28. A. Abizaid The NEVO RES Elution I study: a randomised multicenter comparison of the NEVO reservoir-based Sirolimus eluting-stent with the TAXUS Liberte Paclitaxel-eluting stent: first presentation of the 12-month outcomes Paper presented at: EuroPCR; May 2528, 2010; Paris, France http://www.pcronline. com/Lectures/2010/The-NEVO-RES-Elution-I-study-a-randomised-multicentre- comparison-of-the-NEVO-reservoir-based-Sirolimus-eluting-stent-with-the-TAXUS- Liberte-Paclitaxel-eluting-stent-first-presentation-of-12-month-outcomes Accessed May 29, 2010
29. S. Garg, G. Sarno, and P.W. Serruys The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer EuroIntervention 6 2010 233 239
30. S. Windecker, P.W. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
31. B. Chevalier, S. Silber, and S.-J. Park Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trialphase 2 Circ Cardiovasc Interv 2 2009 188 195
32. S. Verheye, P. Agostoni, and C.L. Dubois 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study J Am Coll Cardiol 53 2009 1031 1039
33. P.R. Stella, R. Mueller, and G. Pavlakis One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial EuroIntervention 4 2008 200 207
34. E. Grube Custom clinical program Paper presented at: EuroPCR; May 1316, 2008; Barcelona, Spain http://www.europcronline.com/fo/lecture/view-slide.php? idCongres=4&id=5514 Accessed June 18, 2009
35. K.D. Dawkins The Element stent technology Paper presented at: EuroPCR; May 25-28, 2010; Paris, France http://www.pcronline.com/Lectures/2010/The- ELEMENT-stent-technology Accessed May 29, 2010
36. E. Grube Bioabsorbable stent The Boston Scientific and REVA technology Paper presented at: EuroPCR; May 1922, 2009; Barcelona, Spain http://www.pcronline.com/Lectures/2009/The-Boston-Scientific-technology Accessed June 10, 2009
37. J.F. Granada The Orbus-Neich EPC-coated bioabsorbable polymer sirolimus-eluting stent program Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA http://www.tctmd.com/ txshow.aspx?tid=939086&id=84030&trid=938634 Accessed October 13, 2009
38. Rutsch W. Multi-center first-in-man study with the lowest known limus dose on the Elixir Medical myolimus eluting coronary stent system with a durable polymer: nine month clinical and six month angiographic and IVUS follow-up. Paper presented at: EuroPCR; May 1922, 2009; Barcelona, Spain.
39. P.A. Lemos, B. Moulin, and M.A. Perin Randomized evaluation of 2 drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial Catheter Cardiovasc Interv 74 2009 665 673
40. P. Vranckx, P.W. Serruys, and S. Gambhir Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9-Month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study EuroIntervention 2 2006 310 317
41. E. Grube, J. Schofer, and K.E. Hauptmann A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent J Am Coll Cardiol Intv 3 2010 431 438
42. R. Waksman, and R. Pakala Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent EuroIntervention 5 Suppl F 2009 F36 F42
43. W.H. De Jong, J. Eelco Bergsma, J.E. Robinson, and R.R. Bos Tissue response to partially in vitro predegraded poly-L-lactide implants Biomaterials 26 2005 1781 1791
44. R.A. Costa Complex patients with coronary artery disease treated with the novel supralimus sirolimus-eluting stents: preliminary results of the prospective, multicentre, non-randomised E-Series trial Paper presented at: EuroPCR; May 19-22, 2009; Barcelona, Spain http://www.pcronline.com/Lectures/ 2009/Complex-patients-with-coronary-artery-disease-treated-with-the-novel- supralimus-sirolimus-eluting-stents-preliminary-results-of-the-prospective- multicentre-non-randomised-E-Series-trial Accessed June 10, 2009
45. P.W. Serruys, G. Sianos, and A. Abizaid The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES) J Am Coll Cardiol 46 2005 253 260
46. U. Kaul, R.K. Gupta, and A. Mathur Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I) Indian Heart J 59 2007 165 172
47. K.D. Dawkins, S. Verheye, and H. Schuhlen The European cobalt STent with Antiproliferative for Restenosis trial (EuroSTAR): 12 month results EuroIntervention 3 2007 82 88
48. M.W. Krucoff, D.J. Kereiakes, and J.L. Petersen A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study J Am Coll Cardiol 51 2008 1543 1552
49. Klauss V. LEADERS: two-year follow-up from a prospective randomized trial of Biolimus A9-eluting stents with a bioabsorbable polymer vs. sirolimus-eluting stents with a durable polymer. Paper presented at: Transcatheter Cardiovascular Therapeutics, September 22, 2009; San Francisco, CA.
50. P. Barlis, E. Regar, and P.W. Serruys An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study Eur Heart J 31 2010 165 176
51. M. Ostojic, D. Sagic, and B. Beleslin First clinical comparison of Nobori Biolimus A9 eluting stents with Cypher sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes EuroIntervention 3 2008 574 579
52. M.I. Hamilos, M. Ostojic, and B. Beleslin Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion J Am Coll Cardiol 51 2008 2123 2129
53. M. Hamilos, J. Sarma, and M. Ostojic Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses Circ Cardiovasc Interv 1 2008 193 200
54. B. Chevalier The NOBORI biolimus-eluting stent: comprehensive update of the clinical trial program Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA http://www.tctmd.com/txshow. aspx?tid=939082&id=84010&trid=938634 Accessed November 29, 2009
55. E. Grube, L. Buellesfeld, and F.J. Neumann Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings Am J Cardiol 99 2007 1691 1697
56. J. Schofer Multicentre, first-in-man study on the Elixir Myolimus-eluting coronary stent system with bioabsorbable polymer: 12-month clinical and angiographic/IVUS results Paper presented at: EuroPCR; May 2528, 2010; Paris, France http://www.pcronline.com/Lectures/2010/Multicentre-first-in-man-study-on- the-Elixir-Myolimus-eluting-coronary-stent-system-with-bioabsorbable-polymer-12- month-clinical-and-angiographic-IVUS-results Accessed May 29, 2010
57. G. Guagliumi, V. Sirbu, and G. Musumeci Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI) Circ Cardiovasc Interv 2010 July 22 [E-pub ahead of print]
58. M.A. Turco, J.A. Ormiston, and J.J. Popma Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial J Am Coll Cardiol 49 2007 1676 1683
59. M.W. Basalus, M.J. Ankone, G.K. van Houwelingen, F.H. de Man, and C. von Birgelen Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy EuroIntervention 5 2009 157 165
60. Y. Otsuka, N.A. Chronos, R.P. Apkarian, and K.A. Robinson Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents J Invasive Cardiol 19 2007 71 76
61. A. Dibra, A. Kastrati, and J. Mehilli Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial Catheter Cardiovasc Interv 65 2005 374 380
62. A. Abizaid PAX A trial (Amazonia PAX versus TAXUS Libert): 4-month follow-up: IVUS and optical coherence tomography evaluation Paper presented at: EuroPCR; May 2528, 2010; Paris, France http://www.pcronline.com/Lectures/2010/ PAX-A-trial-Amazonia-PAX-versus-TAXUS-Liberte-4-month-follow-up-IVUS-and- optical-coherence-tomography-evaluation Accessed May 29, 2010
63. E. Grube BioFreedom First In Man progress report Paper presented at: Transcatheter Cardiovascular Therapeutics; September 24, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid=941378&id=84088&trid=938634 Accessed November 10, 2009
64. J.R. Costa Jr., A. Abizaid, and R. Costa 1-Year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I Trial J Am Coll Cardiol Intv 2 2009 422 427
65. J. Mehilli, A. Kastrati, and R. Wessely Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss Circulation 113 2006 273 279
66. R. Wessely, J. Hausleiter, and C. Michaelis Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating Arterioscler Thromb Vasc Biol 25 2005 748 753
67. J. Hausleiter, A. Kastrati, and R. Wessely Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating Eur Heart J 26 2005 1475 1481
68. P. Moore, P. Barlis, and J. Spiro A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents J Am Coll Cardiol Intv 2 2009 437 444
69. J. Ruef, H. Storger, F. Schwarz, and J. Haase Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions Catheter Cardiovasc Interv 71 2008 333 339
70. R.A. Byrne, R. Iijima, and J. Mehilli Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer J Am Coll Cardiol Intv 2 2009 291 299
71. B.E. Claessen, M.A. Beijk, and V. Legrand Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: the SPIRIT II trial Circ Cardiovasc Interv 2 2009 339 347
72. Raber L. SIRTAX-LATE: five-year clinical and angiographic follow-up from a prospective randomized trial of sirolimus-eluting and paclitaxel-eluting stents. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 22, 2009; San Francisco, CA.
73. J. Aoki, A.C. Abizaid, A.T. Ong, K. Tsuchida, and P.W. Serruys Serial assessment of tissue growth inside and outside the stent after implantation of drug-eluting stent in clinical trials Does delayed neointimal growth exist? EuroIntervention 1 2005 235 255
74. M. Leon The ENDEAVOR and ENDEAVOR Resolute zotarolimus-eluting stent: comprehensive update of the clinical trial program (featuring the first presentation of the ENDEAVOR IV 3-year results) Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid=939082&id=84004&trid=938634 Accessed October 28, 2009
75. N. Tada, R. Virmani, and G. Grant Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model Circ Cardiovasc Interv 3 2010 174 183
76. Virmani R. Are polymer-free DES safer? Observations from experimental studies in animal models. Paper presented at: Transcatheter Therapeutics; September 21, 2009; San Francisco, CA.
77. W.J. van der Giessen, O. Sorop, P.W. Serruys, I. Peters-Krabbendam, and H.M.M. van Beusekom Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing J Am Coll Cardiol Intv 2 2009 284 290
78. A. Abizaid The MIV VESTASYNC polymer-free sirolimus-eluting stent program (micorporous hydroxyapatite surface) Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid=939088&id=84036&trid=938634 Accessed October 10, 2009
79. J. Fajadet The Minvasys Amazonia Pax & Nile Pax polymer free paclitaxel eluting stent programme Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid=939088&id=84034&trid=938634 Accessed October 10, 2009
80. J. Mehilli, R.A. Byrne, and A. Wieczorek Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur Heart J 29 2008 1975 1982
81. R.A. Byrne, S. Kufner, and K. Tiroch Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results Heart 95 2009 1489 1494
82. R.A. Byrne, J. Mehilli, and R. Iijima A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents Eur Heart J 30 2009 923 931
83. R.A. Byrne, A. Kastrati, and K. Tiroch 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug-eluting stents J Am Coll Cardiol 55 2010 2536 2543
84. J.C. Tardif, G. Cote, and J. Lesperance Probucol and multivitamins in the prevention of restenosis after coronary angioplasty Multivitamins and Probucol Study Group N Engl J Med 337 1997 365 372
85. C. Tamburino, A. La Manna, and M.E. Di Salvo First-in-man 1-year clinical outcomes of the Catania coronary stent system with nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial J Am Coll Cardiol Intv 2 2009 197 204
86. S. Windecker, R. Simon, and M. Lins Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial Circulation 111 2005 2617 2622
87. M.A. Beijk, M. Klomp, and N. Verouden Genous endothelial progenitor cell capturing stent versus the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomised, single-centre, pilot study Eur Heart J 31 2010 1055 1064
88. A. La Manna, D. Capodanno, and M. Cera Optical coherence tomographic results at six-month follow-up evaluation of the CATANIA coronary stent system with nanothin Polyzene-F surface modification (from the Assessment of The LAtest Non-Thrombogenic Angioplasty Stent [ATLANTA] trial) Am J Cardiol 103 2009 1551 1555
89. A. La Manna, A. Sanfilippo, and M.E. Di Salvo Short and mid-term benefits of CATANIA stent in acute coronary syndromes [abstract] Am J Cardiol 104 2009 111D
90. La Manna A, Sanfilippo A, Di Salvo ME, et al. One-year outcomes of CATANIA coronary stent system with nanothin polyzene-F in a real-world unselected population: assessment of the latest non-thrombogenic angioplasty stent 2 (Atlanta-2) study. Paper presented at: EuroPCR; May 25-28, 2010; Paris, France.
91. A. Moschovitis, R. Simon, and A. Seidenstucker Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial EuroIntervention 6 2010 63 68
92. P.P. Karjalainen, A. Ylitalo, and M. Niemela Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction Ann Med 41 2009 599 607
93. P.P. Karjalainen, A.P. Annala, A. Ylitalo, T. Vahlberg, and K.E. Airaksinen Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population Int J Cardiol 2009 Apr 27 [E-pub ahead of print]
94. S. Windecker Randomized comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularisation Paper presented at: EuroPCR; May 25-28, 2010, Paris, France http://www.pcronline.com/ Lectures/2010/Comparison-of-titanium-nitride-oxide-coated-stents-with- Zotarolimus-eluting-stents-for-coronary-revascularisation-TIDE-a-randomised- controlled-trial Accessed May 29, 2010
95. T. Inoue, M. Sata, and Y. Hikichi Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis Circulation 115 2007 553 561
96. S. Garg, H.J. Duckers, and P.W. Serruys Endothelial progenitor cell capture stents: will this technology find its niche in contemporary practice? Eur Heart J 31 2010 1032 1035
97. J. Aoki, P.W. Serruys, and H. van Beusekom Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry J Am Coll Cardiol 45 2005 1574 1579
98. H.J. Duckers, S. Silber, and R. de Winter Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent EuroIntervention 3 2007 67 75
99. Duckers H, Onuma Y, Benit E, et al. Final results of the HEALING 2B Trial to evaluate a bioengineered CD34 antibody coated stent (Genous Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. Paper presented at: American Heart Association Scientific Sessions; November 812, 2008; Orlando, FL.
100. Beijk M. Two year follow-up of the endothelial progenitor cell capturing stent versus a paclitaxel-eluting stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: the single-centre randomised TRIAS study. Paper presented at: EuroPCR 2009; May 19-22, 2009; Barcelona, Spain.
101. Winter Rd. Can a pro-healing stent make a difference? Final 12-month outcomes from the e-HEALING 5,000 patient registry using the EPC-coated Genous stent. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 22, 2009; San Francisco, CA.
102. J.F. Granada, S. Inami, and M.S. Aboodi Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix Circ Cardiovasc Interv 3 2010 257 266
103. S.G. Ellis, J.J. Popma, and J.M. Lasala Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial J Am Coll Cardiol 45 2005 1193 1200
104. E. Spuentrup, A. Ruebben, and A. Mahnken Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent Circulation 111 2005 1019 1026
105. J.A. Ormiston, and P.W.S. Serruys Bioabsorbable coronary stents Circ Cardiovasc Interv 2 2009 255 260
106. W.S. Pietrzak, D.R. Sarver, and M.L. Verstynen Bioabsorbable polymer science for the practicing surgeon J Craniofac Surg 8 1997 87 91
107. R. Waksman Biodegradable stents: they do their job and disappear J Invasive Cardiol 18 2006 70 74
108. W.J. van der Giessen, A.M. Lincoff, and R.S. Schwartz Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries Circulation 94 1996 1690 1697
109. H. Tamai, K. Igaki, and E. Kyo Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans Circulation 102 2000 399 404
110. Nishio S, Kosuga K, Okada M, et al. Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents. Paper presented at: EuroPCR; May 25-28, 2010; Paris, France.
111. T. Tsuji, H. Tamai, and K. Igaki Four-year follow-up of the biodegradable stent (IGAKI-TAMAI stent) Circ J 68 2004 135
112. J.A. Ormiston, P.W. Serruys, and E. Regar A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial Lancet 371 2008 899 907
113. P.W. Serruys, J.A. Ormiston, and Y. Onuma A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet 373 2009 897 910
114. P.W. Serruys ABSORB Cohort B trial: 6-month clinical and imaging results of the evaluation of the bioresorbable everolimus-eluting vascular scaffold (BVS) in the treatment of patients with de novo native coronary artery lesions Paper presented at: EuroPCR; May 2528, 2010; Paris, France http://www.pcronline. com/Lectures/2010/ABSORB-Cohort-B-trial-6-month-clinical-and-imaging-results-of- the-evaluation-of-the-bioresorbable-Everolimus-eluting-vascular-scaffold-BVS-in- the-treatment-of-patients-with-de-novo-native-coronary-artery-lesions Accessed May 29, 2010
115. R. Jabara Poly-anhydride based on salicylic acid and adipic acid anhydride Paper presented at: EuroPCR; May 1922, 2009; Barcelona, Spain http://www.pcronline.com/Lectures/2009/Poly-anhydride-based-on-salicylic-acid- and-adipic-acid-anhydride Accessed June 11, 2009
116. R. Erbel, C. Di Mario, and J. Bartunek Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial Lancet 369 2007 1869 1875
117. Y. Onuma, S. Garg, and T. Okamura Ten-year follow-up of the IGAKI-TAMAI stent A post-humous tribute to the scientific work of Dr. Hideo Tamai EuroIntervention 5 Suppl F 2009 F109 F111
118. P.C. Douek, R. Correa, and R. Neville Dose-dependent smooth muscle cell proliferation induced by thermal injury with pulsed infrared lasers Circulation 86 1992 1249 1256
119. M.J. Post, A.N. de Graaf-Bos, H.G. van Zanten, P.G. de Groot, J.J. Sixma, and C. Borst Thrombogenicity of the human arterial wall after interventional thermal injury J Vasc Res 33 1996 156 163
120. T. Yamawaki, H. Shimokawa, and T. Kozai Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo J Am Coll Cardiol 32 1998 780 786
121. F. Vogt, A. Stein, and G. Rettemeier Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent Eur Heart J 25 2004 1330 1340
122. S. Tanimoto, P.W. Serruys, and L. Thuesen Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials Catheter Cardiovasc Interv 70 2007 515 523
123. V. ABBOTT ABSORB trial investigator brochure 2006 ABBOTT Vascular Santa Clara, CA
124. J.A. Ormiston, M.W. Webster, and G. Armstrong First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent Catheter Cardiovasc Interv 69 2007 128 131
125. Y. Onuma, P.W. Serruys, and J.A. Ormiston Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial EuroIntervention 2010 June 6 [E-pub ahead of print]
126. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
127. P.W. Serruys, A.T.L. Ong, and J.J. Piek A randomised comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT First trial EuroIntervention 1 2005 58 65
128. P.W. Serruys, P. Ruygrok, and J. Neuzner A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 2006 286 294
129. G. Sarno, Y. Onuma, and H.M. Garcia IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process Catheter Cardiovasc Interv 75 2010 914 918
130. H.M. Garcia-Garcia, N. Gonzalo, and R. Pawar Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis A substudy of the ABSORB clinical trial EuroIntervention 4 2009 443 448
131. T. Okamura, S. Garg, and J.L. Gutierrez-Chico In-vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the Revision 1.0 and Revision 1.1 stent design in the ABSORB clinical trial EuroIntervention 5 2010 932 938
132. M.J. Pollman Engineering a bioresorbable stent: REVA programme update EuroIntervention 5 Suppl F 2009 F54 F57
133. A. Abizaid The REVA tyrosine polycarbonate bioabsorbable stent: lessons learned and future directions Paper presented at: Transcatheter Therapeutics, September 22, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid= 939090&id=84050&trid=938634 Accessed October 14, 2009
134. R. Jabara, N. Chronos, and K. Robinson Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating Catheter Cardiovasc Interv 72 2008 186 194
135. A. Lafont, and E.A.R.T. Durand : concept of a bioresorbable stent without drug elution EuroIntervention 5 Suppl F 2009 F83 F87
136. J. Yan, and V. Bhat Elixir Medical's bioresorbable drug eluting stent programme: an overview EuroIntervention 5 Suppl F 2009 F80 F82
137. R. Cottone, G.L. Thatcher, and S. Paker Orbus Neich fully absorbable coronary stent platform incorporating dual partitioned coatings EuroIntervention 5 Suppl F 2009 F65 F71
138. R. Waksman, R. Pakala, and P.K. Kuchulakanti Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries Catheter Cardiovasc Interv 68 2006 607 617 discussion 6189
139. B. Heublein, R. Rohde, V. Kaese, M. Niemeyer, W. Hartung, and A. Haverich Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 89 2003 651 656
140. R. Waksman, R. Erbel, and C. Di Mario Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries J Am Coll Cardiol Intv 2 2009 312 320
141. R. Waksman Current state of the absorbable metallic (magnesium) stent EuroIntervention 5 Suppl F 2009 F94 F98
142. U. Sigwart, J. Puel, V. Mirkovitch, F. Joffre, and L. Kappenberger Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty N Engl J Med 316 1987 701 706
143. A. Hirayama, K. Kodama, and T. Adachi Angiographic and clinical outcome of a new self-expanding intracoronary stent (RADIUS): results from multicenter
144. A. Konig, T.M. Schiele, J. Rieber, K. Theisen, H. Mudra, and V. Klauss Stent design-related coronary artery remodeling and patterns of neointima formation following self-expanding and balloon-expandable stent implantation Catheter Cardiovasc Interv 56 2002 478 486
145. M. Joner, G. Nakazawa, and C. Bonsignore Histopathologic evaluation of nitinol self-expanding stents in an animal model of advanced atherosclerotic lesions EuroIntervention 5 2010 737 744
146. N. Tanaka, J.B. Martin, and K. Tokunaga Conformity of carotid stents with vascular anatomy: evaluation in carotid models AJNR Am J Neuroradiol 25 2004 604 607
147. H. Kaneda, F. Ikeno, J. Lyons, M. Rezaee, A.C. Yeung, and P.J. Fitzgerald Long-term histopathologic and IVUS evaluations of a novel coiled sheet stent in porcine carotid arteries Cardiovasc Intervent Radiol 29 2006 413 419
148. J. Hermiller The TriReme Medical Antares sidebranch access stent: design specifications and clinical trial results Paper presented at Transcatheter Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid=938900&id=83226&trid=938634 Accessed November 12, 2009
149. T. Lefevre Invatec twin rail bifurcation stent Paper presented at: Transcatheter Cardiovascular Therapeutics; October 1721, 2005; Washington, DC http://www.tctmd.com/Show.aspx?id=68990 Accessed November 12, 2009
150. T. Lefevre, J. Ormiston, and G. Guagliumi The Frontier stent registry: safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesions J Am Coll Cardiol 46 2005 592 598
151. Van Geuns RJ. The Minvasys Nile paclitaxel-eluting sidebranch access stent: results from the BiPAX study. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA.
152. R.A. Costa BIPAX bifurcation study: first results Paper presented at: EuroPCR; May 25-28, 2010; Paris, France http://www.pcronline.com/Lectures/2010/ Bipax-bifurcation-study-first-results Accessed May 29, 2010
153. J. Ormiston, M. Webster, S. El-Jack, D. McNab, and S.S. Plaumann The AST petal dedicated bifurcation stent: first-in-human experience Catheter Cardiovasc Interv 70 2007 335 340
154. J. Ormiston, T. Lefevre, E. Grube, D. Allocco, and K.D. Dawkins First Human Use of the TAXUS Petal Paclitaxel-Eluting Bifurcation Stent EuroIntervention 6 2010 46 53
155. R.J. Solar The Y Med sidekick stent delivery system for the treatment of coronary bifurcation and ostial lesions Paper presented at: Cardiovascular Revascularization Therapies; March 8, 2007; Washington, DC http://www.crtonline. org/flash.aspx?PAGE-ID=4328 Accessed November 12, 2009
156. F. Ikeno, Y.H. Kim, and J. Luna Acute and long-term outcomes of the novel side access (SLK-View) stent for bifurcation coronary lesions: a multicenter nonrandomized feasibility study Catheter Cardiovasc Interv 67 2006 198 206
157. Y. Onuma, R. Muller, and S. Ramcharitar Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions EuroIntervention 3 2008 546 552
158. H. Doi, A. Maehara, G.S. Mintz, L. Dani, M.B. Leon, and E. Grube Serial intravascular ultrasound analysis of bifurcation lesions treated using the novel self-expanding sideguard side-branch stent Am J Cardiol 104 2009 1216 1221
159. K. Hauptman Bifurcation management using Cappella technology Paper presented at: EuroPCR; May 25-28, 2010; Paris, France http://www.pcronline.com/ index.php/Lectures/2010/Bifurcation-management-using-Cappella-technology Accessed May 30, 2010
160. S. Verheye, E. Grube, and S. Ramcharitar First-in-man (FIM) study of the Stentys bifurcation stent30 days results EuroIntervention 4 2009 566 571
161. S. Verheye The Stentys self-expanding stent: design specification and clinical trial results Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA http://www.tctmd.com/txshow. aspx?tid=938900&id=83230&trid=938634 Accessed November 14, 2009
162. A. Abizaid, J. de Ribamar Costa Jr., and V.J. Alfaro Bifurcated stents: giving to Caesar what is Caesar's EuroIntervention 2 2007 518 525
163. R. Virmani, F.D. Kolodgie, A.P. Burke, A. Farb, and S.M. Schwartz Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions Arterioscler Thromb Vasc Biol 20 2000 1262 1275
164. A. Farb, A.P. Burke, F.D. Kolodgie, and R. Virmani Pathological mechanisms of fatal late coronary stent thrombosis in humans Circulation 108 2003 1701 1706
165. M. Joner, A.V. Finn, and A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
166. J.F. Granada, M. Pomeranz, J. Heringes, and I. Odess vProtect luminal shield system EuroIntervention 3 2007 416 419
167. S. Ramcharitar, N. Gonzalo, and R.J. van Geuns First case of stenting of a vulnerable plaque in the SECRITT I trial-the dawn of a new era? Nat Rev Cardiol 6 2009 374 378
168. D. Chamie, J.R. Costa Jr., and A. Abizaid Serial angiography and intravascular ultrasound: results of the SISC Registry (Stents In Small Coronaries) J Am Coll Cardiol Intv 3 2010 191 202
169. A. Abizaid CardioMind stent Paper presented at: Transcatheter Cardiovascular Therapeutics; September 24, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid=939038&id=81898&trid=938634 Accessed January 26, 2010
170. R. Botelho The CARDIOMIND Sparrow DES program (CARE II): a bioabsorbable polymer sirolimus-eluting "micro-stent." Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid=939086&&id=84612&trid=938634 Accessed October 16, 2009
171. A. Latib, A. Colombo, and G.M. Sangiorgi Bifurcation stenting: current strategies and new devices Heart 95 2009 495 504
172. M. Pan, J.S. de Lezo, and A. Medina Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy Am Heart J 148 2004 857 864
173. A. Colombo, J.W. Moses, and M.C. Morice Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions Circulation 109 2004 1244 1249
174. J.S. Jensen, A. Galløe, and J.F. Lassen Safety in simple versus complex stenting of coronary artery bifurcation lesions The nordic bifurcation study 14-month follow-up results EuroIntervention 4 2008 229
175. D. Hildick-Smith, A.J. de Belder, and N. Cooter Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies Circulation 121 2010 1235 1243
176. A. Colombo, E. Bramucci, and S. Sacca Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) study Circulation 119 2009 71 78
177. S. Brar, W. Gray, and G. Dangas Bifurcation stenting with drug-eluting stents: a meta-analysis EuroIntervention 5 2009 475 484
178. F. Zhang, L. Dong, and J. Ge Simple versus complex stenting strategy for coronary artery bifurcation lesions in the drug-eluting stent era: a meta-analysis of randomized trials Heart 95 2009 1676 1681
179. D.G. Katritsis, G.C.M. Siontis, and J.P.A. Ioannidis Double versus single stenting for coronary bifurcation lesions: a meta-analysis Circ Cardiovasc Intervent 2 2009 409 415
180. A. Erglis, I. Kumsars, and M. Niemela Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic Stent Technique study Circ Cardiovasc Interv 2 2009 27 34
181. L. Ge, I. Iakovou, and J. Cosgrave Treatment of bifurcation lesions with two stents: one year angiographic and clinical follow up of crush versus T stenting Heart 92 2006 371 376
182. T. Yamashita, T. Nishida, and M.G. Adamian Bifurcation lesions: two stents versus one stentimmediate and follow-up results J Am Coll Cardiol 35 2000 1145 1151
183. D.I. Axel, W. Kunert, and C. Goggelmann Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery Circulation 96 1997 636 645
184. C. Herdeg, M. Oberhoff, and A. Baumbach Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo J Am Coll Cardiol 35 2000 1969 1976
185. T. Mori, Y. Kinoshita, A. Watanabe, T. Yamaguchi, K. Hosokawa, and H. Honjo Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro Cancer Chemother Pharmacol 58 2006 665 672
186. B. Scheller, C. Hehrlein, and W. Bocksch Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter N Engl J Med 355 2006 2113 2124
187. B. Scheller, C. Hehrlein, and W. Bocksch Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter Clin Res Cardiol 97 2008 773 781
188. M. Unverdorben, C. Vallbracht, and B. Cremers Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis Circulation 119 2009 2986 2994
189. L.S. Maier, C. Maack, O. Ritter, and M. Bohm Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008 (PEPCAD, LokalTax, INH, German ablation registry, German device registry, DES.DE registry, DHR, Reality, SWEETHEART registry, ADMA, GERSHWIN) Clin Res Cardiol 97 2008 356 363
190. Hamm C. Paclitaxel-eluting PTCA-balloon in combination with the Coroflex Blue stent vs. The sirolimus coated Cypher stent in the treatment of advanced coronary artery disease. Paper presented at: American Heart Association Scientific Sessions 2009; November 14, 2009; Orlando, FL.
191. B. Cortese, A. Micheli, and A. Picchi Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO Study Heart 96 2010 1291 1296
192. C. Herdeg, K. Gohring-Frischholz, and K.K. Haase Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation Circ Cardiovasc Interv 2 2009 294 301
193. M. Unverdorben Summarizing the B. Braun PEPCAD coronary paclitaxel-eluting balloon clinical studies Paper presented at: Transcatheter Cardiovascular Therapeutics; September 22, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid=939092&id=84062&trid=938634 Accessed January 14, 2010
194. J.C. Fanggiday, P.R. Stella, S.H. Guyomi, and P.A. Doevendans Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions: the DEBIUT (drug-eluting balloon in bifurcation Utrecht) registry Catheter Cardiovasc Interv 71 2008 629 635
195. D.G. Mathey The PEPCAD V bifurcation study Paper presented at: Transcatheter Cardiovascular Therapeutics; September 22, 2009; San Francisco, CA http://www.tctmd.com/txshow.aspx?tid=939092&id=84154&trid=938634 Accessed January 14, 2010
196. B. Scheller, U. Speck, C. Abramjuk, U. Bernhardt, M. Bohm, and G. Nickenig Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis Circulation 110 2004 810 814
197. P. Stella Drug eluting balloons in coronary bifurcations: the Drug Eluting Balloon In Bifurcation trial Paper presented at: EuroPCR; May 2528, 2010; Paris, France http://www.pcronline.com/Lectures/2010/The-DEBIUT-trial Accessed May 29, 2010